Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice

1 Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial The Lancet, May 16, 2013

2 A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and osteoporosis research with alendronate and leuprolide (coral) study European Urology, May 2, 2013

3 Vitamin D and systemic lupus erythematosus: an update Expert Review of Clinical Immunology, May 9, 2013    Review Article

4 The effectiveness of teriparatide in the clinical practice-attenuation of the bone mineral density outcome by increasing age and bisphosphonate pretreatment Annals of Medicine, May 22, 2013    Evidence Based Medicine

5 Prevention of steroid-induced low bone mineral density in children with renal diseases: a systematic review Nephrology Dialysis Transplantation, May 6, 2013    Evidence Based Medicine    Review Article

6 Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease Rheumatology International, May 9, 2013

7 A randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis Hepatology, May 21, 2013

8 A cluster-randomised, controlled trial to assess the impact of a workplace osteoporosis prevention intervention on the dietary and physical activity behaviours of working women: study protocol BMC Public Health, April 30, 2013

9 Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines Journal of Andrology, May 22, 2013

10 Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole Journal of Cancer Research & Clinical Oncology, May 17, 2013